BACKGROUND: Device thrombosis is one of the main complications in left ventricular assist devices (LVAD) therapy and remains a challenging issue. Data on device thrombosis management, especially on the application of direct thrombin inhibitors such as argatroban, is limited and a consensus on thrombosis management has not yet been established. METHODS: In this study we analysed retrospective clinical data obtained from 26 patients on VAD therapy who received argatroban for suspected VAD thrombosis, between April, 2012 and February, 2017. RESULTS: Thirteen patients (50%) showed resolution of thrombus after argatroban therapy. Eight of 26 patients (30.8%) were free of thrombotic events 90 days after discharge. Argatroban therapy was unsuccessful in 13 patients of the study cohort, leading to subsequent VAD-exchange. Six of 13 patients with first VAD-exchange had no thrombotic events 90 days after discharge. Six patients (23.1%) suffered from bleeding, especially gastrointestinal bleeding. No hemorrhagic strokes were observed. Three patients (11.5%) did not survive the follow-up period. CONCLUSIONS: Argatroban appears to be an alternative to other pharmacological treatment options in VAD thrombosis. Efficacy and safety characteristics are acceptable, but further investigation on larger populations is necessary.
BACKGROUND: Device thrombosis is one of the main complications in left ventricular assist devices (LVAD) therapy and remains a challenging issue. Data on device thrombosis management, especially on the application of direct thrombin inhibitors such as argatroban, is limited and a consensus on thrombosis management has not yet been established. METHODS: In this study we analysed retrospective clinical data obtained from 26 patients on VAD therapy who received argatroban for suspected VAD thrombosis, between April, 2012 and February, 2017. RESULTS: Thirteen patients (50%) showed resolution of thrombus after argatroban therapy. Eight of 26 patients (30.8%) were free of thrombotic events 90 days after discharge. Argatroban therapy was unsuccessful in 13 patients of the study cohort, leading to subsequent VAD-exchange. Six of 13 patients with first VAD-exchange had no thrombotic events 90 days after discharge. Six patients (23.1%) suffered from bleeding, especially gastrointestinal bleeding. No hemorrhagic strokes were observed. Three patients (11.5%) did not survive the follow-up period. CONCLUSIONS: Argatroban appears to be an alternative to other pharmacological treatment options in VAD thrombosis. Efficacy and safety characteristics are acceptable, but further investigation on larger populations is necessary.
Entities:
Keywords:
Left ventricular assist device (LVAD); VAD thrombosis; anticoagulation; argatroban; lysis
Authors: David Feldman; Salpy V Pamboukian; Jeffrey J Teuteberg; Emma Birks; Katherine Lietz; Stephanie A Moore; Jeffrey A Morgan; Francisco Arabia; Mary E Bauman; Hoger W Buchholz; Mario Deng; Marc L Dickstein; Aly El-Banayosy; Tonya Elliot; Daniel J Goldstein; Kathleen L Grady; Kylie Jones; Katarzyna Hryniewicz; Ranjit John; Annemarie Kaan; Shimon Kusne; Matthias Loebe; M Patricia Massicotte; Nader Moazami; Paul Mohacsi; Martha Mooney; Thomas Nelson; Francis Pagani; William Perry; Evgenij V Potapov; J Eduardo Rame; Stuart D Russell; Erik N Sorensen; Benjamin Sun; Martin Strueber; Abeel A Mangi; Michael G Petty; Joseph Rogers Journal: J Heart Lung Transplant Date: 2013-02 Impact factor: 10.247
Authors: Jan D Schmitto; Daniel Zimpfer; Arnt E Fiane; Robert Larbalestier; Steven Tsui; Paul Jansz; Andre Simon; Stephan Schueler; Martin Strueber Journal: Eur J Cardiothorac Surg Date: 2016-07-13 Impact factor: 4.191
Authors: Randall C Starling; Nader Moazami; Scott C Silvestry; Gregory Ewald; Joseph G Rogers; Carmelo A Milano; J Eduardo Rame; Michael A Acker; Eugene H Blackstone; John Ehrlinger; Lucy Thuita; Maria M Mountis; Edward G Soltesz; Bruce W Lytle; Nicholas G Smedira Journal: N Engl J Med Date: 2013-11-27 Impact factor: 91.245
Authors: Nader Moazami; Carmelo A Milano; Ranjit John; Benjamin Sun; Robert M Adamson; Francis D Pagani; Nicholas Smedira; Mark S Slaughter; David J Farrar; O Howard Frazier Journal: Ann Thorac Surg Date: 2012-12-20 Impact factor: 4.330
Authors: Jan D Schmitto; Jasmin S Hanke; Sebastian Rojas; Murat Avsar; Doris Malehsa; Christoph Bara; Martin Strueber; Axel Haverich Journal: J Cardiothorac Surg Date: 2015-08-08 Impact factor: 1.637